Drug-related hepatotoxicity.

  title={Drug-related hepatotoxicity.},
  author={Victor J. Navarro and John R. Senior},
  journal={The New England journal of medicine},
  volume={354 7},
  • V. Navarro, J. Senior
  • Published 16 February 2006
  • Medicine, Biology
  • The New England journal of medicine
Given its rarity, drug-related hepatotoxicity may not be seen during the initial clinical trials of a new medication. After approval, when many more patients are exposed, toxic effects that are very infrequent may emerge. This review explains the difficulties in identifying the cause of hepatotoxic effects in such situations and provides clinical guidance with regard to the detection, evaluation, and possible prevention of drug-related hepatotoxicity. 

Figures and Tables from this paper

Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
Drug-induced liver disease.
  • T. Davern
  • Medicine, Biology
    Clinics in liver disease
  • 2012
Drug hepatotoxicity from a regulatory perspective.
  • J. Senior
  • Medicine
    Clinics in liver disease
  • 2007
Antituberculosis Drug-Induced Hepatotoxicity: Incidence, Mechanism and Management
Hydrazine, a toxic metabolite of isoniazid, is responsible for hepatotoxicity, the first or the second most reported ADR resulting in treatment interruption.
Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical Data
The pattern of antibacterial DILI is reviewed and detail is provided on molecular mechanisms and toxicogenomics, as well asclinical data based on epidemiology studies, to increase the awareness and understanding of druginduced liver injury (DILI) due to antibacterial drugs.
Cancer chemotherapy I: hepatocellular injury.
Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database
The main aim of this study was to determine the most frequently reported drugs to the Serbian Pharmacovigilance Database (SPD) with suspected induced hepatotoxicity. Additionally, reasons for the low
Immune Mechanisms in Drug-Induced Hepatotoxicity
Clinically, DILI mimics all forms of liver diseases, with the liver damage varying in severity from mild and transient increases in serum aminotransferases to fulminant hepatic failure, and represents an important diagnostic and therapeutic challenge for physicians.
Mortality associated with drug-induced liver injury (DILI).
Idiosyncratic drug-induced liver injury (DILI) is an important cause of liver failure and liver injury leading to transplantation, although in most cases self-remitting when administration of the


Drug-induced hepatotoxicity.
  • W. M. Lee
  • Medicine
    The New England journal of medicine
  • 1995
Causality assessment in drug-induced hepatotoxicity
The use of diagnostic algorithms may add consistency to the diagnostic process either by translating the suspicion into a quantitative score or by providing a framework that emphasises the features that merit attention in cases of suspected hepatic adverse reactions.
Genetic predisposition to drug-induced hepatotoxicity.
Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.
  • D. Larrey
  • Medicine, Biology
    Seminars in liver disease
  • 2002
Important directions for the future include prospective studies of the incidence of hepatic adverse drug reactions, finding specific markers that augment or replace causality assessment, and further elucidating the role of the genetic and environmental factors that contribute to individual susceptibility.
Drug-Induced Liver Injury
  • G. Abboud, N. Kaplowitz
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
Mitigating the potential for drug-induced liver injury is achieved by the identification of toxicity signals during clinical trials and the monitoring of liver tests in clinical practice.
Insight into hepatotoxicity: The troglitazone experience
In the 4 years since the withdrawal of troglitazone, there has been a major increase in interest in drug induced liver disease (DILI) and the sense of urgency within industry to improve means of screening out liver liabilities at early phases of drug development.
Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions
There is need for prospective safety studies to establish the true incidence of DILI caused by a drug, to identify risk factors for it, and to collect biologic materials for analytic studies toward better understanding mechanisms of D ILI.
Drug‐induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia
Ductopenia might be the consequence of acute cholangitis; the degree of ductopenia and the chronicity of the disease might be directly related to the severity of the early acute damage of bile ducts.
Pharmacogenomics--drug disposition, drug targets, and side effects.
The existence of large population differences with small intrapatient variability is consistent with inheritance as a determinant of drug response; it is estimated that genetics can account for 20 to 95 percent of variability in drug disposition and effects.